Literature DB >> 21827502

Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood.

Laura Tonnetti1, Aaron M Thorp, Heather L Reddy, Shawn D Keil, Raymond P Goodrich, David A Leiby.   

Abstract

BACKGROUND: Trypanosoma cruzi, the protozoan parasitic agent of Chagas disease, can be transmitted by blood transfusion. In 2007, most US blood banks started screening blood donations for T. cruzi, but the cost and perceived need of the test have been the subject of ongoing discussion. In this study, we evaluated the ability of the Mirasol System (CaridianBCT), which uses riboflavin (RB) and ultraviolet light to inactivate pathogens, to reduce the levels of infectious T. cruzi in whole blood (WB). STUDY DESIGN AND METHODS: WB units were inoculated with 4, 40, 400, and 4000 trypomastigotes/mL. After addition of RB and illumination at various energy levels, the samples were tested for the presence of live parasites by hemoculture.
RESULTS: All preillumination samples exhibited T. cruzi growth in hemoculture, while postillumination samples from units containing 4 and 40 trypomastigotes/mL showed no signs of viable parasites after 16 weeks of culture. In contrast, at both 400 and 4000 parasites/mL, two of the three units were positive for viable parasites.
CONCLUSIONS: The total log reduction observed for T. cruzi was 3.5 log or greater, but less than 4.5 log. This level of reduction is likely to be orders of magnitude higher than what would be expected in a tainted blood donation, indicating that the Mirasol System could be effective at preventing transfusion of the causative agent of Chagas disease.
© 2012 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21827502     DOI: 10.1111/j.1537-2995.2011.03285.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  11 in total

Review 1.  Chagas disease and transfusion medicine: a perspective from non-endemic countries.

Authors:  Andrea Angheben; Lucia Boix; Dora Buonfrate; Federico Gobbi; Zeno Bisoffi; Simonetta Pupella; Giorgio Gandini; Giuseppe Aprili
Journal:  Blood Transfus       Date:  2015-10       Impact factor: 3.443

Review 2.  Emerging Pathogens - How Safe is Blood?

Authors:  Michael Schmidt; Wolf-Jochen Geilenkeuser; Walid Sireis; Erhard Seifried; Kai Hourfar
Journal:  Transfus Med Hemother       Date:  2013-12-27       Impact factor: 3.747

Review 3.  Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology.

Authors:  Susan Yonemura; Suzann Doane; Shawn Keil; Raymond Goodrich; Heather Pidcoke; Marcia Cardoso
Journal:  Blood Transfus       Date:  2017-05-11       Impact factor: 3.443

4.  Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood.

Authors:  Rachael P Jackman; Marcus O Muench; Heather Inglis; John W Heitman; Susanne Marschner; Raymond P Goodrich; Philip J Norris
Journal:  Transfusion       Date:  2016-11-18       Impact factor: 3.157

5.  Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time.

Authors:  Heather F Pidcoke; Steve J McFaul; Anand K Ramasubramanian; Bijaya K Parida; Alex G Mora; Chriselda G Fedyk; Krystal K Valdez-Delgado; Robbie K Montgomery; Kristin M Reddoch; Armando C Rodriguez; James K Aden; John A Jones; Ron S Bryant; Michael R Scherer; Heather L Reddy; Raymond P Goodrich; Andrew P Cap
Journal:  Transfusion       Date:  2013-01       Impact factor: 3.157

6.  Red Blood Cells Derived from Whole Blood Treated with Riboflavin and UV Light Maintain Adequate Cell Quality through 21 Days of Storage.

Authors:  Lina Y Dimberg; Suzann K Doane; Susan Yonemura; Heather L Reddy; Nick Hovenga; E Jane Gosney; Melissa Tran; Shilo Wilkinson; Raymond P Goodrich; Susanne Marschner
Journal:  Transfus Med Hemother       Date:  2019-02-22       Impact factor: 3.747

7.  Treatment of Whole Blood With Riboflavin and UV Light: Impact on Malaria Parasite Viability and Whole Blood Storage.

Authors:  Shirley Owusu-Ofori; Joseph Kusi; Alex Owusu-Ofori; Graham Freimanis; Christine Olver; Caitlyn R Martinez; Shilo Wilkinson; Janna M Mundt; Shawn D Keil; Raymond P Goodrich; Jean-Pierre Allain
Journal:  Shock       Date:  2015-08       Impact factor: 3.454

8.  Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026).

Authors:  Chintamani Atreya; Simone Glynn; Michael Busch; Steve Kleinman; Edward Snyder; Sara Rutter; James AuBuchon; Willy Flegel; David Reeve; Dana Devine; Claudia Cohn; Brian Custer; Raymond Goodrich; Richard J Benjamin; Anna Razatos; Jose Cancelas; Stephen Wagner; Michelle Maclean; Monique Gelderman; Andrew Cap; Paul Ness
Journal:  Transfusion       Date:  2019-05-29       Impact factor: 3.157

9.  Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium.

Authors:  Geraldine M Walsh; Andrew W Shih; Ziad Solh; Mia Golder; Peter Schubert; Margaret Fearon; William P Sheffield
Journal:  Transfus Med Rev       Date:  2016-02-23

10.  Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation.

Authors:  Steve Kleinman; Adonis Stassinopoulos
Journal:  Transfusion       Date:  2015-08-25       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.